The combination of an experimental BioAge Labs drug with the approved Eli Lilly obesity medication Zepbound has hit a major setback: a safety signal observed in some clinical trial participants that ...
BioAge Labs, Inc. (BIOA) Securities Class Action: The lawsuit, Soto v. BioAge Labs, Inc., filed in the U.S. District Court for the Northern District of California, centers on the company's STRIDES ...
Interest in metabolic medicines is riding high, led by the popular class of weight management drugs known as GLP-1 agonists. BioAge Labs aims to help those medications work better with a lead drug ...
Kristen Fortney, PhD, CEO and co-founder, is scheduled to participate in a fireside chat on Thursday, February 26 from 10:40 AM to 11:05 AM ET. Fortney and Dov Goldstein, MD, CFO, will participate in ...
Advancement of lead candidate BGE-102, an oral, brain-penetrant NLRP3 inhibitor for obesity, with initial clinical data expected 2H25 New strategic collaboration with Lilly ExploR&D expands ...
SAN FRANCISCO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- BioAge Labs (NASDAQ: BIOA), a biopharmaceutical company focused on metabolic diseases, is facing a class-action lawsuit from shareholders who allege ...
Oral NLRP3 inhibitor BGE-102 on track for Phase 1 initiation in 2H 2025 with initial data by year-end Expanded APJ agonist pipeline through option agreement for novel antibody and advancement of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results